Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by TriumphSpitSixon Nov 14, 2018 3:03am

221 Views

Post# 28970146

RE:share price and reverse split

What "looming reverse split" exactly?

You mean the standard Annual Meeting blurb about a possible share consolidation that almost EVERY company votes on EVERY year but NEVER actually executes?

Fearmonger!

youngpupper wrote: its almost a double whammy, the lack of share price appreciate means a bigger reverse split will need to happen, but investors are shying away because of a looming reverse split

trials in 2019 will be the defining moments for Antibe, and whether we see a 1:10 or a 1:2 RS to list on major US exchanges.

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December